{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "esgPopulated": false, "market": "gb_market", "longName": "ERYTECH Pharma S.A.", "marketState": "CLOSED", "regularMarketPrice": 1.02733, "messageBoardId": "finmb_24677080", "exchange": "LSE", "shortName": "ERYTECH PHARMA SA ERYTECH PHARM", "exchangeTimezoneShortName": "BST", "exchangeTimezoneName": "Europe/London", "regularMarketChangePercent": 1.1151583, "gmtOffSetMilliseconds": 3600000, "fiftyTwoWeekLowChange": 0.64549005, "fiftyTwoWeekLowChangePercent": 1.6904726, "fiftyTwoWeekRange": "0.38184 - 1.28838", "fiftyTwoWeekHighChange": -0.26105, "fiftyTwoWeekHighChangePercent": -0.20261878, "fiftyTwoWeekLow": 0.38184, "fiftyTwoWeekHigh": 1.28838, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.733, "firstTradeDateMilliseconds": 1411110000000, "priceHint": 4, "regularMarketChange": 0.0113300085, "regularMarketTime": 1683902759, "regularMarketDayHigh": 1.07, "regularMarketDayRange": "1.02733 - 1.07", "regularMarketDayLow": 1.02733, "regularMarketVolume": 44977, "regularMarketPreviousClose": 1.016, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "EUR", "regularMarketOpen": 1.07, "averageDailyVolume3Month": 15308, "averageDailyVolume10Day": 21484, "sharesOutstanding": 17937500, "bookValue": 0.757, "fiftyDayAverage": 0.865183, "fiftyDayAverageChange": 0.16214705, "fiftyDayAverageChangePercent": 0.18741359, "twoHundredDayAverage": 0.83219904, "twoHundredDayAverageChange": 0.195131, "twoHundredDayAverageChangePercent": 0.23447636, "marketCap": 159347, "priceToBook": 1.357107, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "0QSS.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "60 Avenue Rockefeller", "address2": "B\u00e2timent Ad\u00e9nine", "city": "Lyon", "zip": "69008", "country": "France", "phone": "33 4 78 74 44 38", "fax": "33 4 78 75 56 29", "website": "https://www.erytech.com", "industry": "", "sector": "", "longBusinessSummary": "ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gil  Beyen M.B.A.", "age": 60, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 572427, "fmt": "572.43k", "longFmt": "572,427"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Soyer Ph.D.", "age": 56, "title": "Deputy GM, CFO & COO", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 379723, "fmt": "379.72k", "longFmt": "379,723"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. J\u00e9r\u00f4me  Bailly Pharm.D.", "age": 43, "title": "Deputy GM of Operations, Chief Quality Officer & Qualified Person", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 247910, "fmt": "247.91k", "longFmt": "247,910"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Naomi  Eichenbaum", "title": "Director Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anne-C\u00e9cile  Fumey", "age": 47, "title": "HR Director", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Iman  El-Hariry M.D., Ph.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Karine  Charton Ph.D.", "title": "Director of Innovation & Valorization", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Philip L. Lorenzi", "title": "Consultant & Member of Scientific Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Eric  Raymond M.D., Ph.D.", "title": "Consultant & Member of Scientific Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Bridget  Bax", "title": "Consultant & Member of Scientific Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}